Another interesting prognostic biomarker may be represented by STK11 (serine/threonine kinase 11), one of the most mutated tumor-suppressor genes in NSCLC, that seems to be frequently associated with KRAS mutations. The gene discussed is STK11; the disease is non-small cell lung carcinoma.